Bronchiectasis Exacerbation Increases the Risk of Adverse Renal Outcomes—Results From a Large Territory‐Wide Cohort Study
The Clinical Respiratory Journal · 2025
DOI: 10.1111/crj.70029 ↗Kurz gefasst
Kohortenstudie in der Zeitschrift The Clinical Respiratory Journal, 2025. Verfasst von Wang Chun Kwok und 6 weiteren Autor:innen. Beteiligte Einrichtung: Division of Respiratory Medicine and Critical Care Medicine, Department of Medicine, Queen Mary Hospital, The University of Hong Kong, Pok Fu Lam, Ho…. Hauptthemen laut MEDLINE: Bronchiectasis, Acute Kidney Injury. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 45 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Introduction
Bronchiectasis exacerbation (BE) is associated with unfavorable sequelae in other organs such as the cardiovascular system; data regarding its impact on adverse term renal outcomes, however, is lacking.
Methods
A territory‐wide retrospective cohort study was conducted in Hong Kong between 1/1/1993 and 31/12/2017. All patients with bronchiectasis followed in the public healthcare system in 2017 were classified as “Exacerbators” or “Non‐Exacerbators,” and their adverse renal outcomes (renal progression [decrease in eGFR by 30 mL/min lasted for more than 12 months during follow up], acute kidney injury [AKI], and annual rate of eGFR decline) in the ensuing 7 years were compared. Results were also analyzed in the 1:1 propensity score matched (PSM) cohort.
Results
A total of 7929 patients (1074 “Exacerbators” group and 6855 “Non‐exacerbators”) were followed for 6.2 ± 1.6 years. A total of 1570 patients (19.8%) had renal progression, and 935 (11.8%) patients developed AKI. “Exacerbators” showed significantly increased risk of renal progression (adjusted odds ratio [aOR] 1. 27 [95% CI 1.08–1.50, p = 0.003]), more rapid eGFR decline (−3.67 [−1.74 to −6.54] vs. −3.03 [−1.56 to −5.12] mL/min/1.73 m 2 /year, p = 0.004) and AKI (aOR 1.99; 95% CI 1.44–2.73, p < 0.001) than the “Non‐exacerbators.” Annual number of BE was associated with renal progression (aOR 1.45; 95% CI 1.22–1.72, p < 0.001) and AKI (aOR 2.00; 95% CI 1.38–2.91, p < 0.001). Results were consistent in the analysis with the PSM cohort.
Conclusions
Renal progression and AKI are common among patients with bronchiectasis, and BE is an independent risk factor for adverse renal outcomes.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Division of Respiratory Medicine and Critical Care Medicine, Department of Medicine, Queen Mary Hospital, The University of Hong Kong, Pok Fu Lam, Hong Kong SAR, China.
- Department of Statistics, The Chinese University of Hong Kong, Sha Tin, Hong Kong SAR, China.
- Division of Nephrology, Department of Medicine, Queen Mary Hospital, The University of Hong Kong, Pok Fu Lam, Hong Kong SAR, China.
Zitieren
APA
Kwok, W. C., Tsui, C. K., Sze Him Isaac, L., Wong, C. K. E., Tam, T. C. C., Ho, J. C. M., & Yap, D. Y. H. (2025). Bronchiectasis Exacerbation Increases the Risk of Adverse Renal Outcomes—Results From a Large Territory‐Wide Cohort Study. The Clinical Respiratory Journal. https://doi.org/10.1111/crj.70029
Vancouver
Kwok WC, Tsui CK, Sze Him Isaac L, Wong CKE, Tam TCC, Ho JCM, et al. Bronchiectasis Exacerbation Increases the Risk of Adverse Renal Outcomes—Results From a Large Territory‐Wide Cohort Study. The Clinical Respiratory Journal. 2025. doi:10.1111/crj.70029
BibTeX
@article{Kwok2025,
author = {Kwok, Wang Chun and Tsui, Chung Ki and Sze Him Isaac, Leung and Wong, Chun Ka Emmanuel and Tam, Terence Chi Chun and Ho, James Chung Man and Yap, Desmond Yat Hin},
title = {Bronchiectasis Exacerbation Increases the Risk of Adverse Renal Outcomes—Results From a Large Territory‐Wide Cohort Study},
journal = {The Clinical Respiratory Journal},
year = {2025},
doi = {10.1111/crj.70029}
}
EUVIMED